The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer
Open Access
- 23 June 2021
- journal article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (2), 109-123
- https://doi.org/10.17709/2409-2231-2021-8-2-10
Abstract
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC). Nowadays, immune response checkpoint inhibitors (monoclonal antibodies) are actively introduced into clinical practice which demonstrated significant improvements in the overall survival for patients with unresectable NSCLC. These drugs block programmed cell death protein (PD‑1) and programmed cell death ligand 1 (PD-L1) that increases regulation on the surface of T-cells and improves the patient's immune system respond to tumor cells. In 2019, durvalumab was introduced into clinical practice for the treatment of patients with unresectable NSCLC (stage III) after chemoradiotherapy. In our study, we’ve summarizes studies investigated the feasibility and safety of radiotherapy with immunotherapy for locally advanced lung cancer.Keywords
This publication has 54 references indexed in Scilit:
- Immunotherapy in first-line treatment of recurrent non-small cell lung cancerMedical Council, 2019
- Durvalumab in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy in a real practiceJournal of Modern Oncology, 2019
- The combination of immunotherapy and radiation therapy for non-small cell lung cancerOnkologiya. Zhurnal imeni P.A.Gertsena, 2018
- Immuno-oncology: new possibilities of drug therapy for solid tumorsOnkologiya. Zhurnal imeni P.A.Gertsena, 2017
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Targeted therapy for locally advanced non-small-cell lung cancer with EGFR mutationOnkologiya. Zhurnal imeni P.A.Gertsena, 2016
- T-cell exhaustion in the tumor microenvironmentCell Death & Disease, 2015
- The Concept of Immunological SurveillancePublished by S. Karger AG ,2015
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Occurrence of malignancy in immunodeficiency diseases: A literature reviewCancer, 1971